Galectin Therapeutics Inc. Stock Forecast

NASDAQ:GALT Open Broker Account

$1.20 (-3.76%)

Volume: 54.037k

Closed: Dec 02, 2022

Hollow Logo Score: -6.134

Galectin Therapeutics Inc. Stock Forecast

$1.20 (-3.76%)

Volume: 54.037k

Closed: Dec 02, 2022

Score Hollow Logo -6.134

Galectin Therapeutics Inc. Stock Statistics NASDAQ:GALT

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior. Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average. Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Dates Signal Change
2022-11-25 - 2022-12-02 SELL -6.74
2022-11-23 - 2022-11-25 HOLD -5.15
2022-11-18 - 2022-11-23 SELL 2.26
2022-11-17 - 2022-11-18 HOLD -2.21
2022-10-21 - 2022-11-17 SELL -9.33

Stock Score Effectiveness

Bollinger Stock Signal Effectiveness

Macd Signal Effectiveness

Mv7 Signal Effectiveness

Score signal

Bollinger Signal Statistics

MV signal statistics

MACD Signal Statistics

Hot Stocks To Watch:

About Galectin Therapeutics Inc.

Galectin Therapeutics Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti... GALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT